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Helen DakinAbstract
Systematic literature searches were conducted to identify studies that conducted statistical mapping to predict
EQ-5D utilities or responses from any source instrument and reported the estimated algorithms in sufficient detail
to allow other researchers to use them to predict EQ-5D in other studies. Ninety studies reporting 121 mapping
algorithms met the inclusion criteria. The studies estimated EQ-5D utilities from 80 source instruments. All but two
studies included direct utility mapping to predict EQ-5D utilities, while 20 studies (22%) conducted response
mapping to predict responses to each EQ-5D domain. Seventy-two studies (80%) explored ordinary least squares
regression and 16 (18%) used censored least absolute deviations (CLAD) models. The details of the studies
identified are made available in an online database, which will be updated regularly to enable researchers to easily
identify studies that can help them to estimate utilities for economic evaluation.
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Estimation of quality-adjusted life-years (QALYs) for
economic evaluation requires data on health-related
quality of life on a preference-based “utility” scale that
captures preferences about the values of different health
states on a scale from one (perfect health) through zero
(death) to negative values (states worse than dead). Al-
though several such preference-based quality of life mea-
sures have been developed, EQ-5D (EuroQoL) is the
most commonly used [1] and some health technology
assessment organisations (including the UK National In-
stitute for Health and Care Excellence, NICE [2]) specif-
ically request that EQ-5D is used in all economic
evaluations submitted to them to ensure comparability
between studies.
Since many studies collect data on non-preference-
based measures of quality of life or clinical symptoms,
but not EQ-5D, there is substantial demand for mapping
algorithms that use statistical analyses to predict EQ-5D
responses or utilities from responses or scores on other
measures. Although other reviews of mapping studies
have been conducted previously [3-8], at least 40 studiesCorrespondence: helen.dakin@dph.ox.ac.uk
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reproduction in any medium, provided the orhave been published since even the most recent study [7]
was conducted and many older studies are also omitted from
these previous reviews. An up-to-date, publicly-available
database of mapping studies would help researchers to iden-
tify studies mapping between the instruments of interest,
which is currently difficult, as there is no specific Medical
Subject Headings (MeSH) term, several different terms used
in the literature (e.g. mapping, mapped, crosswalk and re-
gression) and many studies are published only as discussion
or conference papers. It is also often difficult to identify stud-
ies extending the results of previous mapping studies by re-
fining model specification, conducting external validation or
developing tools to estimate predictions. This study therefore
aimed to conduct a structured literature review identifying
studies mapping to EQ-5D, which will be updated regularly
and made publicly available.Review
Methods
Systematic literature searches were conducted to identify
all studies mapping to EQ-5D. Medline (via Pubmed),
the Centre for Reviews and Dissemination (CRD, www.
crd.york.ac.uk/crdweb) database (which includes DARE,
NHS EED and HTA) and the Health Economists’ Study
Group website (www.hesg.org.uk) were searched in De-
cember 2012 and in July 2013 using key words thatis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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“crosswalk” or “transfer to utility”. The EuroQoL
Reference Search (www.euroqol.org) was searched in
April and July 2013. The reference lists of previous
systematic reviews of mapping studies, estimation of
utilities or use of mapping in health technology as-
sessment [3-8] were also reviewed. EMBASE was not
searched due to resource constraints and as most
studies that are in EMBASE but not Medline comprise
conference abstracts that are less likely to report coeffi-
cients for mapping models. Studies meeting the following
inclusion/exclusion criteria were included:
 Conduct statistical mapping (including, but not
limited to, regression analyses) to predict EQ-5D
utilities and/or responses from any source
instrument. Studies using judgement mapping (in
which researchers, experts or patients make
judgements about how EQ-5D items relate to those
on the source instrument) were excluded. Studies
that simply reported the mean EQ-5D utility for
different subgroups categorised by the source
instrument were excluded unless such data were
specifically reported with the intention of being used
for mapping.
 Report algorithms or coefficients in sufficient detail
that other researchers can use them to predict
EQ-5D utilities and/or responses in other studies.
 No restrictions by publication date or status were
imposed providing that the article was available in
English.
 Papers validating an existing mapping algorithm or
developing tools to estimate predictions were
identified and linked to the source study in the
online database but were not counted as separate
studies unless they also estimated new mapping
models not reported previously. Similarly, early
versions of articles (e.g. conference or discussion
papers) meeting inclusion criteria were not counted
separately unless they presented additional mapping
algorithms; instead such studies are linked to the
final version in the online database.
 Valuation studies directly estimating health state
valuations (e.g. using visual analogue, time trade-off
or standard gamble) rather than EQ-5D were
excluded.
Data were extracted on: citation details; the source in-
strument(s); the clinical area (classified using ICD-10
chapter headings); the number of paired observations of
EQ-5D and source instruments used to estimate map-
ping models; and the types of statistical model/method
evaluated. Where necessary, authors were contacted for
clarification or additional information. All model types/specifications evaluated were recorded, regardless of
which were considered to fit the data best or had coeffi-
cients reported. In the narrative review, key statistics are
presented either by paper or by mapping algorithm,
where a mapping algorithm is defined as prediction of
EQ-5D from one source measure (or set of measures) to
EQ-5D using a given dataset. For simplicity, mapping al-
gorithms reported in the same paper that map from the
same source instrument to the same target instrument
are counted only once, regardless of how many different
model specifications were explored or presented. A
study mapping from SF-12 to EQ-5D and from SF-36 to
EQ-5D using both ordinary least squares (OLS) and Tobit
regression is therefore counted as two mapping algo-
rithms (one from SF-12 to EQ-5D and one from SF-36).
To simplify data extraction, no quality assessment was
conducted.
Results
Ninety studies reporting 121 mapping algorithms met
inclusion criteria. Fourteen other identified studies were
excluded as they did not report regression coefficients
[9-22]. Full details of all included studies are available at:
www.herc.ox.ac.uk/downloads/mappingdatabase. The num-
ber of studies published each year has increased substantially
(Figure 1) over the past 15 years from one study per year in
2000–2003 to 17 studies in 2012 and 2013. The steepest in-
creases occurred in 2009 and 2012, which follow the publi-
cation of the 2008 NICE methods guide endorsing mapping
in the absence of directly measured EQ-5D [23] and the
technical support document giving guidance on mapping
methodology [24].
All but two [25,26] of the 90 included studies used
some form of direct utility mapping, in which a statis-
tical model predicts EQ-5D utility. Twenty studies (22%)
[25,27-39] estimated response mapping models (also
known as “indirect” mapping), in which EQ-5D re-
sponses for each of the five domains are predicted using
categorical regression techniques (e.g. multinomial logis-
tic regression) or cross-tabulation, thereby giving map-
ping models that can be used with any EQ-5D tariff.
Seventy-two studies (80%) evaluated linear models as-
suming Gaussian residuals (e.g. OLS), of which 35 (39%)
studies evaluated only linear models, and 37 (41%) eval-
uated these alongside other specifications. Fourteen
studies (16%) used Tobit models and 16 (18%) used cen-
sored least absolute deviations (CLAD) to allow for cen-
soring. Generalised linear models (GLM) were used in
eight studies (9%) and two-part models (such as those
where one model predicted the probability of having
perfect health and a second predicted utility conditional
on having imperfect health) were used in nine studies
(10%). Three studies did not clearly state their methods,
while 40 used more than one model type.
Figure 1 Number of mapping papers by year of publication.
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including: latent class or mixture models [40-43]; spline
or locally piecewise regression [43,44]; fractional polyno-
mial regression [45,46]; generalised least squares [47,48];
fractional logit [27,33]; random-effects or mixed models
[33,49]; and median regression [50]. Dakin et al. [27] de-
veloped a three-part model, which comprised a multi-
nomial logit to predict the probability of having perfect
health or having severe problems on any domain (N3),
followed by two models predicting utility conditional on
having moderate problems, or on having severe prob-
lems. Rowen et al. obtained visual analogue scale valua-
tions and responses on different questionnaires and used
OLS to map each instrument to visual analogue and
then onto one another [51]. van Hout et al. also explored
non-parametric cross-tabulation and a psychometric
scaling approach, which uses item response theory to
implement response mapping [38]. Richardson et al. [52]
used geometric mean squares, which allows for the error
in both the source and target instrument and ensures
that models are logically coherent [19]. Among the stud-
ies excluded from the review due to not reporting suffi-
cient information to estimate predicted EQ-5D utility,
two used Bayesian probability networks [10,18]; this
technique gave models with extremely good prediction
accuracy, although it is unclear whether it is practical to
publish such algorithms for use in other studies.
Eighty different source instruments (including combi-
nations of two or more instruments or subscales) were
mapped to EQ-5D. The Health Assessment Question-
naire (HAQ) was the most commonly mapped sourceinstrument (15 models; Table 1). Thirteen models esti-
mated EQ-5D utilities from SF-6D, SF-12 or SF-36 and a
further 12 mapped from one of the European Organization
for Research and Treatment of Cancer (EORTC) quality of
life questionnaires. Eight source further instruments were
each mapped in more than two studies (Table 1). In total,
33 models (27%) mapped from generic (rather than
condition-specific) measures, in contrast to 63% of the
studies identified by Brazier et al. [3] and 10% of recent
NICE appraisals using mapping [6].
Sixteen mapping models (13%) were estimated on gen-
eral population samples and 14 (12%) included mixed
samples with a variety of conditions (Table 1). Twenty-
eight studies (23%) were on musculoskeletal disease,
which may, at least in part, be driven by the number of
large datasets and NICE appraisals in this area. The
remaining studies covered most ICD-10 chapters, al-
though only two studies covered infectious disease and
none examined haematological, obstetric or gynaeco-
logical conditions. Value in Health comprised the jour-
nal publishing the greatest number of mapping studies
(20 studies) followed by Quality of Life Research (10
studies) and Medical Decision Making and Health and
Quality of Life Outcomes (nine studies each). Many of
the remaining studies were reported in disease-specific
clinical journals.
The sample size used to estimate mapping models
ranged from 48 to 134,269 observations, with median
1,167 and mean 6,069 (standard deviation: 17,289); 21
algorithms (17%) were estimated using < 200 observa-
tions (Table 1) and 16 (13%) used ≥10,000. For 19






Barthel index 3 (2%)
28-joint disease activity score (DAS 28) 3 (2%)
Dermatology Life Quality Index (DLQI) 3 (2%)
European Organization for Research and
Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ), all variants
12 (10%)
Functional Assessment of Cancer Therapy
(FACT), all variants
5 (4%)
HAQ (including modified HAQ and HAQ-DI) 15 (12%)
Modified Rankin scale (mRS) 3 (2%)
Numerical rating scale or visual analogue 4 (3%)
Parkinson’s Disease Questionnaire (PDQ-8 &
PDQ-39)
5 (4%)
Short form variants (SF-6D, SF-12, SF-36) 13 (11%)
25-item Visual Functioning Questionnaire (VFQ-25) 3 (2%)
Other generic measures 15 (12%)




Central nervous system 12 (10%)
Digestive system 5 (4%)
Eye conditions 3 (2%)
General population 16 (13%)
Mental health and behavioural disorders 4 (3%)
Musculoskeletal 28 (23%)




Sample size (number of observations in the
estimation sample, including repeated
measurements of the same patients)






≥ 100,000 2 (2%)
Not clearly stated 19 (16%)
*Numbers do not sum to the total as four studies predicted EQ-5D based on
two instruments simultaneously (e.g. fitting a model predicting EQ-5D based
on questions from both FACT and EORTC).
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estimate mapping models was not clearly stated: gener-
ally as repeated observations of an unstated number of
participants were included in the estimation sample.
Conclusions
The database of mapping studies available at http://www.
herc.ox.ac.uk/downloads/mappingdatabase (Additional file 1)
provides researchers planning cost-utility analyses with an
easy-to-access resource that helps them to identify map-
ping algorithms linking the instruments of interest. Details
of any studies validating other mapping algorithms and
any supplementary information downloadable from other
sites, such as tools available to generate predictions, are
also given. The database will be updated regularly as new
studies are published and in the future may be extended
to include studies mapping to other measures and/or ex-
tract data on additional fields if funding becomes available.
The database may help with study identification in future
reviews of utility estimation in specific disease areas and
for reviewers and editors assessing the novelty of a new
mapping algorithm. The database may also be useful for
researchers developing a new mapping algorithm or valid-
ating an existing one to avoid duplicate publication and
identify best practice. Duplication of previous work ap-
pears to be common, with 49% of mapping models using
a source instrument that had been evaluated in a previous
mapping study, although some duplication may be appro-
priate if the relationship between instruments differs be-
tween disease areas or if the new study uses superior
methods or data. For HAQ, for example, two studies used
mixture models [41,42], although the remainder used lin-
ear models with or without polynomial terms and/or ran-
dom effects, and frequently generated very similar
mapping models.
However, as with all studies, mapping models vary in
quality and relevance to particular clinical problems. In
particular, 17% of mapping models used < 200 observa-
tions and 39% of studies used OLS alone, which assumes
that EQ-5D utilities are normally distributed with no
ceiling effect, but often gives good prediction accuracy.
Studies also varied substantially in prediction accuracy
and in the completeness with which the estimation sample
and model selection procedures were described. Re-
searchers considering using a particular mapping algo-
rithm in their study should review the quality of the
study(ies) linking the instruments of interest (e.g. using
[6]) and assess whether the sample(s) used in the develop-
ment or validation of the algorithm in question encom-
passes the type of patients included in their study, to
avoid extrapolating beyond the estimation sample [6].
At present, there is relatively little evidence on the extent
to which mapping algorithms developed in one population
generalise to another and general population samples may
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to accurately estimate utilities across the entire range.
Sample size, availability of additional covariates and suit-
ability of the algorithm to be used with secondary data
may comprise additional considerations that may affect
the choice of which algorithm to use in any given study.
By searching a wide range of databases up to early
2013, my review identified 90 studies, of which only 39
(43%) were identified in previous reviews. Most of the
studies identified for the first time here were either pub-
lished in 2011–2013 or were economic evaluations that
also developed mapping algorithms. The main limitation
of this review is that EMBASE was not searched; as re-
sult, some studies (e.g. conference abstracts) may have
been missed. Furthermore, some studies reported only
in the grey literature (such as reports for funders, NICE
manufacturer submissions or conference papers) may
have been missed. Coefficients may also be available
from the authors for some studies that were excluded
from the review on the grounds that the algorithms were
not published in sufficient detail to allow them to be
used in other studies.
The review also suggests that the more complex model
specifications (e.g. response mapping or mixture models)
are gaining in popularity and highlights a variety of
model specifications that have been used in a small
number of studies and warrant further investigation.
Mixture models [41], response mapping and non-parametric
cross-tabulation [38] may be particularly useful for allowing
for the non-Gaussian distribution of utilities when the sam-
ple size is sufficiently large. Improvements to study reporting
are also warranted: in particular, researchers should clearly
report the number of observations included in the estima-
tion sample and ensure that the full mapping algorithm is
made available for other researchers to use. Finally, mapping
should always be considered second best to direct EQ-5D
measurement, since it introduces additional errors and as-
sumptions: the existence of published mapping algorithms is
no substitute for inclusion of appropriate utility instruments
within clinical trials.Additional file
Additional file 1: The master version of the database is available at
http://www.herc.ox.ac.uk/downloads/mappingdatabase and will be
updated regularly as more studies are published.Abbreviations
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